Keytruda

Fierce Pharma

Merck unveils $3B cost-cutting plan

CEO Rob Davis called the restructuring a “multiyear optimization initiative” that will redirect resources from mature franchise to new growth drivers.

Kevin Dunleavy Jul 29, 2025 8:15am

Businessman climbing steps to pluck a star from the sky

Merus hails 'unprecedented' survival on solid tumor bispecific

May 23, 2025 7:35am

Immutep's LAG-3 agent posts 'impressive' survival data

May 5, 2025 10:37am

Flexibility and adaptation concept Arrows on cubes following a flexible path

'One of the lucky few': Bicara CEO on last year's $326M IPO

Apr 14, 2025 3:59pm

share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm

Merck's LAG-3 combo fails colorectal cancer phase 3 study

Sep 25, 2024 8:35am